Unmet Needs for Patients With Advanced RAI-R-DTC
Dr Lori Wirth highlights remaining unmet needs and challenges in the treatment of advanced RAI-R-DTC.
The Impact of Molecular Alterations in Advanced RAI-R-DTC Treatment Decision-Making
Lori Wirth, MD, explains why the importance of molecular alterations in her treatment decision-making for a patient with advanced RAI-R-DTC, and the other factors she considers for an appropriate treatment.
Standard of Care Treatment for Patients with Advanced RAI-R-DTC
Lori Wirth, MD, explains what regimen is considered to be the standard-of-care treatment for patients with advanced RAI-R-DTC.
Review of Clinical Trial Data Investigating the Treatment of Advanced RAI-R-DTC
Dr Lori Wirth discusses the design and data of two key clinical trials that led to the approval of the current treatment options for patients with advanced RAI-R-DTC.
Common Molecular Alterations in Advanced RAI-R-DTC
Dr Lori Wirth details the common molecular alterations seen in patients with advanced RAO-R-DTC and which testing platforms she recommends.
Defining Differentiated Thyroid Cancer (DTC) and Radioactive Iodine-Refractory Differentiated Thyroid Cancer (DAI-R-DTC)
Lori Wirth, MD, provides an overview of differentiated thyroid cancer (DTC) and radioactive iodine-refractory differentiated thyroid cancer (RAI-R-DTC).
Real-World Outcomes Data on Lenvatinib as Monotherapy in Patients with RAI-R-DTC
Dr Lori Wirth reviews real-world outcomes data on lenvatinib treatment in patients with RAI-R-DTC and how they compare to the SELECT trial.
NCCN Guideline Updates on Lenvatinib for the Treatment of Advanced RAI-R-DTC
Dr Wirth reviews the updated NCCN guidelines that gave lenvatinib a category 1 recommendation for first-line treatment in advanced RAI-R-DTC and shares her experience of lenvatinib in clinical practice.
Managing Adverse Events of Lenvatinib in Patients with RAI-R-DTC
A key opinion leader explains the adverse events usually seen with lenvatinib treatment in patients with RAI-R-DTC, and the best management strategies.
Treatment Options for Advanced RAI-R-DTC After Progression on Lenvatinib
Lori Wirth, MD, describes the available treatment options for patients with advanced RAI-R-DTC who progress after first-line treatment with lenvatinib.
Investigational Agents and Ongoing Clinical Trials in Advanced RAI-R-DTC
Dr Lori Wirth highlights exciting clinical trials in advanced RAI-R-DTC and investigational agents to look out for in the future.
An Overview of Advanced Radioactive Iodine-Refractory Differentiated Thyroid Cancer (RAI-R-DTC)
Lori Wirth, MD, provides a brief overview of advanced radioactive iodine-refractory differentiated thyroid cancer, or RAI-R-DTC.
Novel Approach to Next-Generation Sequencing of NTRK Tumors
Lori J. Wirth, MD, discusses a new assay with the ability to perform DNA and RNA sequencing to better detect gene fusions.
NTRK Inhibitor Treatment for Patients With Thyroid Cancers
Lori J. Wirth, MD, explains the role of NTRK inhibitor in TRK fusion-positive thyroid cancer treatment.
Sequencing Therapies for Advanced Thyroid Cancer After an NTRK Inhibitor
Lori J. Wirth, MD, discusses sequencing therapies for patients with NTRK fusion–positive advanced thyroid cancer.
Selecting Treatment for NTRK-Positive Iodine-Refractory Thyroid Cancer
Lori J. Wirth, MD, discusses the treatment options now available for patients with iodine-refractory differentiated thyroid cancer.
Using Targeted Therapies for NTRK-Fusion-Positive Thyroid Cancer
Lori Wirth, MD, discusses her experience with NTRK-targeted therapies for patients with thyroid cancer.
Larotrectinib Shows High Efficacy in Differentiated Thyroid Cancer
Lori Wirth, MD, discusses the subanalysis of patients with thyroid cancer with NTRK fusion mutations in clinical trials for larotrectinib.
Future Considerations in the Management of Differentiated Thyroid Cancer
Lori Wirth, MD, discusses unmet needs and future considerations in the management of differentiated thyroid cancer.
Post Hoc Analysis of Patients With Lung Metastases from the SELECT Trial
Lori Wirth, MD, reviews key efficacy data from the post hoc analysis of the SELECT trial investigating the use of lenvatinib in patients with lung metastases.
Clinical Practice Implications From the SELECT Trial
An overview of how SELECT trial data affected clinical treatment practice for patients with differentiated thyroid cancer.
Treatment Options for Patients With Radioiodine-Refractory Metastatic Disease
Medical oncologist Lori Wirth, MD, discusses treatment options for patients with radioiodine-refractory metastatic disease.
Treatment Options for Patients With Differentiated Thyroid Cancer
Lori Wirth, MD, discusses treatment options and potential adverse effects for differentiated thyroid cancer.
Overview and Diagnosis of Differentiated Thyroid Cancer
Lori Wirth, MD, provides an overview and diagnosis consideration of differentiated thyroid cancer and its related subtypes.
DTC Management: Advice and the Future of Treatment
TKI Therapy: Impact of Age and Adverse Events
Differentiated Thyroid Cancer: Initial Management
A 64-Year-Old Man With Differentiated Thyroid Cancer
A discussion on the management of a 64-year-old man with differentiated thyroid cancer, with special consider of the phase 3 SELECT trial regimen.
Recommendations for Treatment of RR-DTC
2 Clarke Drive Cranbury, NJ 08512